Coronavirus outbreak disrupts drug trial for spondyloarthritis, and other Chinese studies

Alan Condon -   Print  |

Several clinical trials in China have been put on hold due to the coronavirus outbreak, including a treatment for a type of spondyloarthritis, according to Reuters.

Chinese company Tasly Pharmaceutical Group is investigating the safety and efficacy of its Jitongning Tablet in improving joint function and pain symptoms in active axial spondyloarthritis patients.

Researchers working on the spondyloarthritis clinical trial Wuhan, China, told Reuters the study has been suspended at their hospital due to the spread of the COVID-19, the name of the disease caused by the coronavirus.

Almost 500 clinical trials are taking place at facilities in Wuhan. 

Roughly 20 percent of global trials are conducted in China, up from about 10 percent five years ago, according to GlobalData.

More articles on biologics:
Spinal fusion will be performed for 'decades to come': Key thoughts from 4 surgeons
Challenges facing private practices in spine, and strategies to tackle them
10 numbers that show how big Johnson & Johnson is in spine, orthopedics

© Copyright ASC COMMUNICATIONS 2020. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers